EN DE
Watch DBV Technologies S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

DBV Technologies S.A. (DBV) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of DBV Technologies S.A. stock €0.36, price €1.80, that is 80.1% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0010417345

DT DBV Technologies S.A. logo Thin data Nov 4, 2026

DBV Technologies S.A.

DBV · PA
Very expensive, weak quality

Our calculation puts a fair price 80% below what the stock costs today.

Low debt
Revenue last quarter 42% below a year ago.
Fair value €0.3570 · Strongly overvalued (−80.1%)
Quality 35/100
Weak Growth (revenue 5y −13.0 %/yr in USD)
Negative free cash flow
Trails peers (1/7)
Narrow moat 17/100
Thin data
⚠ Dilution
Watch DBV Technologies S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€9.59 €0.5100 Fair Value €0.3570 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range €0.5100 – €9.59 · fair‑value band €0.2380 – €0.4505 · the €1.80 price screens above the €0.3570 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow DBV Technologies in your weekly email

Every Wednesday you see whether DBV Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Show moreShow less

Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy.

It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Stock analysis

DBV Technologies S.A. (DBV) currently trades at €1.80, while our model-based Fair Value estimate is €0.3570, 80% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: €0.2380 (bear) to €0.4505 (bull), the price of €1.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

DBV Technologies S.A. reported revenue of $5.6M in FY2025 versus $5.7M in FY2021, a compound −0.3%/yr. Reported net income was −$153M in FY2025.

Key figures

Market cap €778M Small · EPS (TTM) €−0.5200 · Return on equity −206% · Return on assets (EBIT) −78.7% (5-year average) · Operating margin −4,044% · Revenue (TTM) $3.8M · Revenue growth (YoY) −42.3% · Free cash flow −$127M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (medium confidence).

What moves the price

The share trades about 58% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, DBV screens richer than that median.

Fair Value models

Bear €0.2380 Fair Value €0.3570 Bull €0.4505
Price €1.80 · Downside -80.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.2800 €0.4200 €0.5300 54
All 1 models by family
Asset-Based
NCAV (Graham) €0.2800 €0.4200 €0.5300 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 66
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 76
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+35.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.0%
Start year 2020 (pandemic). Over 10 years: +37.1% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,727.6% (2020) → −2,819.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DBV screens overvalued: fair value 80% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare DBV Technologies S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −80.1% · Bottom 25%
Profitability
Return on assets −65.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −42.3% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.14× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs DBV
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs DBV
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs DBV
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs DBV
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs DBV
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs DBV
argenx SE ARGX $927.21 $908.40 −2% vs DBV
CSL Limited CSL A$202.04 A$183.04 −9% vs DBV
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs DBV
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs DBV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DBV Technologies S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "DBV Technologies S.A. Fair Value". https://www.fairvalue-calculator.com/stock/DBV

Frequently asked questions

Is DBV Technologies S.A. (DBV) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of €0.3570 versus a price of €1.80, about 80% lower (overvalued).
What is the fair value of DBV?
Our model-based fair value for DBV Technologies S.A. is €0.3570 (as of Nov 4, 2026), built from audited fundamentals. The current price: €1.80.
What is the quality score of DBV?
DBV Technologies S.A. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DBV Technologies S.A. (DBV)?
Our model-based price target is the fair value of €0.3570 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario €0.2380, optimistic scenario €0.4505. It is a calculation from audited fundamentals, not an analyst target.
What is the DBV Technologies S.A. stock forecast for 2026?
Our models put fair value at €0.3570, about 80% lower versus a price of €1.80 (overvalued). Cautious scenario €0.2380, optimistic scenario €0.4505. The calculation is refreshed regularly with new filings.
What is the revenue of DBV Technologies S.A. (DBV)?
DBV Technologies S.A. reported trailing-twelve-month revenue of about $3.8M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of DBV Technologies S.A. (DBV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DBV Technologies S.A. it is €0.3570 per share (as of Nov 4, 2026), against a price of €1.80. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is DBV Technologies S.A. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, DBV trades above its calculated fair value: price €1.80, fair value €0.3570, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DBV?
No. The price is what the market pays today (€1.80); the fair value is what the company's own numbers justify (€0.3570). For DBV Technologies S.A. the two are €1.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is DBV Technologies S.A. worth?
The market values DBV Technologies S.A. at about €778M (market capitalisation, as of Nov 4, 2026). Per share that is €1.80; our models calculate a fair value of €0.3570 per share.
What do the bullish and bearish scenarios say about DBV?
Our models span a range for DBV Technologies S.A.: cautious scenario €0.2380, base €0.3570, optimistic €0.4505 per share (as of Nov 4, 2026, price €1.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DBV Technologies S.A. (DBV)?
Balance-sheet figures for DBV Technologies S.A. (as of Nov 4, 2026): return on equity −205.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is DBV from its 52-week high?
DBV Technologies S.A. trades at €1.80, about 58% below its 52-week high of €4.27 and 14% above the low of €1.57 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.3570 is for.
Which stocks are comparable to DBV Technologies S.A.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DBV Technologies S.A. stock attractive at the current price?
The data as of Nov 4, 2026: price €1.80, calculated fair value €0.3570 (−80%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DBV calculated?
We run DBV Technologies S.A. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €0.3570 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. DBV Technologies S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DBV Technologies S.A. (DBV)?
The closing price on Nov 6, 2026 was €1.80. Our model-based fair value is €0.3570, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DBV Technologies S.A. right now?
The price sits above even our optimistic bull case (€0.4505). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.2380 to €0.4505) leaves room in how you read the outcome.

Key figures of DBV Technologies S.A.

How large is the market capitalisation of DBV Technologies S.A. (DBV)?
The market capitalisation of DBV Technologies S.A. is €778M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of DBV Technologies S.A. (DBV)?
Earnings per share at DBV Technologies S.A. are €−0.5200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of DBV Technologies S.A. (DBV)?
The return on equity (ROE) of DBV Technologies S.A. is −206% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DBV Technologies S.A. (DBV)?
On an EBIT basis the return on assets of DBV Technologies S.A. is −78.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DBV Technologies S.A. (DBV)?
The operating margin of DBV Technologies S.A. is −4,044% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DBV Technologies S.A. (DBV)?
Revenue at DBV Technologies S.A. is growing −42.3% versus a year earlier (3y avg +5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does DBV Technologies S.A. (DBV) generate?
The free cash flow of DBV Technologies S.A. is −$127M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does DBV Technologies S.A. (DBV) hold?
DBV Technologies S.A. holds more cash than debt, $173M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch DBV Technologies S.A. in the live analysis

One click puts DBV Technologies S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.